These findings suggest a key role for miR-31–5p/CTR binding in promoting atrial fibrosis and arrhythmogenesis, and represents a first example of an RNA-based therapeutic capable of reversing established fibrosis that forms an AF substrate. The gene discussed is CALCR; the disease is atrial fibrillation.